Equities

ReNeuron Group PLC

RENE:LSE

ReNeuron Group PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)3.38
  • Today's Change0.00 / 0.00%
  • Shares traded177.62k
  • 1 Year change-59.09%
  • Beta1.1898
Data delayed at least 20 minutes, as of Feb 05 2024 14:22 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year ReNeuron Group PLC grew revenues 31.51% from 403.00k to 530.00k while net income improved from a loss of 9.69m to a smaller loss of 5.41m.
Gross margin--
Net profit margin-2,037.35%
Operating margin-2,466.27%
Return on assets-50.10%
Return on equity-106.77%
Return on investment-101.09%
More ▼

Cash flow in GBPView more

In 2023, cash reserves at ReNeuron Group PLC fell by 3.40m. However, Cash Flow from Investing totalled 3.91m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 7.48m for operations while cash used for financing totalled 147.00k.
Cash flow per share-0.0841
Price/Cash flow per share--
Book value per share0.0424
Tangible book value per share0.0391
More ▼

Balance sheet in GBPView more

ReNeuron Group PLC appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 3.19% of the market capitalization can be attributed to its 6.15m and debt could be paid in full if management chose.
Current ratio1.51
Quick ratio--
Total debt/total equity0.1425
Total debt/total capital0.1247
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.